725 related articles for article (PubMed ID: 15584937)
21. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
Roffi M; Chew DP; Mukherjee D; Bhatt DL; White JA; Heeschen C; Hamm CW; Moliterno DJ; Califf RM; White HD; Kleiman NS; Théroux P; Topol EJ
Circulation; 2001 Dec; 104(23):2767-71. PubMed ID: 11733392
[TBL] [Abstract][Full Text] [Related]
22. Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department.
Hoekstra J
J Emerg Med; 2000 Oct; 19(3 Suppl):13S-19S. PubMed ID: 11050379
[TBL] [Abstract][Full Text] [Related]
23. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
Glaser R; Glick HA; Herrmann HC; Kimmel SE
J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
[TBL] [Abstract][Full Text] [Related]
24. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
25. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
26. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.
McKay RG; Boden WE
Curr Opin Cardiol; 2001 Nov; 16(6):364-9. PubMed ID: 11704707
[TBL] [Abstract][Full Text] [Related]
27. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
28. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
29. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
Tricoci P; Newby LK; Kandzari DE; Harrington RA
Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665
[TBL] [Abstract][Full Text] [Related]
30. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
De Luca G; Navarese E; Marino P
Eur Heart J; 2009 Nov; 30(22):2705-13. PubMed ID: 19875386
[TBL] [Abstract][Full Text] [Related]
31. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
32. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
33. [Role of GP IIb/IIIa blockers in clinical cardiology].
Rossi ML; Merlini PA
Recenti Prog Med; 2003 Oct; 94(10):440-3. PubMed ID: 14619191
[TBL] [Abstract][Full Text] [Related]
34. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
[No Abstract] [Full Text] [Related]
35. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB
J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822
[TBL] [Abstract][Full Text] [Related]
36. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
[TBL] [Abstract][Full Text] [Related]
37. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
[TBL] [Abstract][Full Text] [Related]
38. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
39. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Roe MT; Sapp SK; Lincoff AM
Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
[TBL] [Abstract][Full Text] [Related]
40. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
De Luca G; Savonitto S; van't Hof AW; Suryapranata H
Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
